The Minnesota Legislature has about two weeks left in the 2022 Legislative Session.
Minnesota Academy of Family Physicians (MAFP) legislative rep Dave Renner, CAE, provides an update from the Capitol on the passage of frontline worker pay; continued movement on MAFP priority issues (e.g., updates to the All-Payer Claims Database, rural primary care residency training funding and limits to mid-year formulary changes); mental health support for health care workers and more.
Read More Two Weeks to Go in MN Legislative Session: Health-Care-Related Updates
Minnesota Academy of Family Physicians (MAFP) legislative rep Dave Renner, CAE, shares the latest health-care-related updates from the Minnesota Legislature, including highlights from last week’s hearing on the Minnesota House Health and Human Services omnibus bill; the extension of the state’s reinsurance program; movement to pass opioid legislation; and support for addressing health care worker mental health and well-being.
Read More 2022 MN Legislative Session Update: Health & Human Services Omnibus Bill, Reinsurance Program Extended + More
Our legislative rep Dave Renner, CAE, shares an update from the Capitol on loan forgiveness for health care workers, funding for tobacco cessation services, proposed limits on Minnesota’s immunization registry, frontline worker payments, physicians running for the Senate in 2022 and more.
Read More 2022 MN Legislative Update: Loan Forgiveness, Frontline Worker Pay & More
Dave Renner, CAE, Minnesota Academy of Family Physicians legislative rep, shares updates on legislation regarding tobacco prevention, mid-year formulary changes, postpartum health care coverage and medical cannabis.
Read More Tobacco Prevention, Formularies, Postpartum Coverage & More
Dave Renner, CAE, our legislative rep, recaps recent movement at the Minnesota State Capitol related to drug prices and formularies, childhood immunizations, MinnesotaCare expansion, mask mandates, hospital pricing and tobacco cessation funding.
Read More Legislative Update: Movement on Limits on Drug Prices, Formulary Changes & More